Systemic Lupus Erythematosus – Epidemiology – Asia-Pacific

Clarivate Epidemiology’s coverage of systemic lupus erythematosus (SLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of SLE for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s SLE forecast will answer the following questions:

• Of all people with SLE, how many in each of the developed countries have been formally diagnosed?
• OOf all people diagnosed with SLE, how many in each developed country across the world are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SLE over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following SLE patient populations:

• Diagnosed prevalent cases of SLE by clinical definition.
• Diagnosed incident cases of SLE by clinical definition.
• Diagnosed prevalent cases of SLE with lupus nephritis.
• Diagnosed drug-treated prevalent cases of SLE with lupus nephritis.
• Diagnosed prevalent cases of SLE with no flares or persistently active disease.
• Diagnosed prevalent cases of SLE with flares only.
• Diagnosed prevalent cases of SLE with persistently active disease only.
• Diagnosed prevalent cases of SLE with flares and persistently active disease.

Note: Coverage may vary by country.